▶ CEREBROLYSIN · SUBTOPIC · MECHANISM
CEREBROLYSIN Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Porcine-brain-derived peptide preparation containing free amino acids and short biologically active peptides (15-25% peptides, MW <10 kDa). Acts on multiple neurotrophic pathways (BDNF, NGF, GDNF, CNTF). Marketed by EVER Neuro Pharma (Austria) in 50+ countries for stroke recovery, traumatic brain injury, and vascular dementia.
PHARMACOKINETIC HALF-LIFE
Reported half-life for CEREBROLYSIN: Variable (peptide mixture). Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISM CATEGORIES
CEREBROLYSIN is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
Neurotrophic blends co-administer multiple peptides or peptide-containing extracts targeting neuronal survival, synaptic plasticity, and neuroprotection. Cerebrolysin is a porcine-brain-derived peptide preparation containing free amino acids and short biologically active peptides marketed in Europe and Asia for stroke recovery and cognitive impairment. The blend acts on BDNF, NGF, GDNF, and CNTF pathways, distinguishing it from single-target neurotrophic peptides like Semax.
Neurotrophic signaling encompasses BDNF, NGF, and the broader neurotrophin family, acting through Trk receptor tyrosine kinases. BDNF / TrkB signaling drives synaptic plasticity, neuronal survival, and learning. Semax is the most-studied research neurotrophic peptide.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Muresanu 2016 (PMID 26786114) CARS Phase 3 reported improvement on modified Rankin Scale in moderate-severe ischemic stroke recovery.
Multiple Phase 2/3 trials in vascular dementia and mild cognitive impairment with mixed but generally favorable readouts.
European clinical literature describes use as adjunct in TBI rehabilitation.
Mixed results in Alzheimer's trials. Not FDA-approved for any neurodegenerative indication.
MECHANISM Q+A
▶ Cerebrolysin vs Semax · what's the difference?
Semax is a single synthetic heptapeptide derived from ACTH(4-10) with primary BDNF / TrkB neurotrophic mechanism. Cerebrolysin is a multi-peptide preparation acting on multiple neurotrophic pathways simultaneously. Cerebrolysin has the larger evidence base with multiple Phase 3 trials; Semax has Russian-language primary literature.
CITED LITERATURE
- Muresanu DF, Heiss WD, Hoemberg V, et al.. Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke 2016. PMID 26786114. link
- Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Hömberg V, Rahlfs VW, Bajenaru O, Popescu BO, Muresanu D. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci 2018. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25